All inspectors · Key sources (PDF) · STEMI shock sheet (PDF)
The STEMI with cardiogenic shock one-pagerOpen it in a new tab

The patient in front of you

Mr. R., 64, arrives with an anterior STEMI and is already in shock: systolic pressure in the 80s on norepinephrine, lactate rising, ejection fraction about 25% on echo. He is awake and following commands. His culprit artery has been opened, and he is now in the cardiac ICU; he still needs a vasopressor, and the order set offers both norepinephrine and dopamine. The shock course follows him from the cath lab to the ICU; each trial answers one decision in his care.

This page helps you decide: Mr. R. needs a vasopressor. Norepinephrine or dopamine?

After this page you can

Your routine for every trial

Work through the six steps in order. Each question at the end belongs to one step, and the answer is on that step's page.

  1. Who was studied? Which patients could enter, which could not, and how sick were they?
  2. Compared with what? What did one group get that the other did not, and what was measured?
  3. What was the main result? Both percentages, the effect size with its 95% CI, and the number needed to treat (and to harm).
  4. Any design traps? Blinding, the choice of endpoint, how close the CI comes to no effect, how long it took, who paid.
  5. Does it apply to my patient? Would my patient have been allowed into the trial?
  6. What did it change? What the guideline now says, and what the trial does not tell you.

Take-home

For Mr. R., a patient in cardiogenic shock who needs a vasopressor, keep norepinephrine rather than switching to dopamine: SOAP II showed no survival gain with dopamine, about one extra arrhythmic event for every 9 patients, and more deaths in its cardiogenic-shock subgroup, a signal rather than proof. On the one-pager it sits on page 2, in the “Vasoactive drugs — lowest dose, shortest time” table (Norepinephrine and Dopamine rows).